Form 4: Emergent BioSolutions EVP, Chief Financial Officer Richard S. Lindahl Reports Stock Option Grant
SEC Form 4 Filing
Richard S. Lindahl, EVP and CFO of Emergent BioSolutions, reports the acquisition of 125,000 employee stock options.
Summary
- Richard S. Lindahl, the EVP and Chief Financial Officer of Emergent BioSolutions Inc., filed a Form 4 with the SEC.
- The filing reports the acquisition of 125,000 employee stock options on March 13, 2024, at an exercise price of $2.33.
- These options vest in three equal installments beginning on March 12, 2031.
- Following the reported transaction, Lindahl beneficially owns 305,944 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of transaction: Acquisition of 125,000 employee stock options. |
| 03/12/2031 | Options vest in three equal installments beginning on the day prior to the anniversary date of the grant. |
| 03/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.